Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). Together the entitlement offer and institutional placement raised gross proceeds of A$97 million, including A$36.7 million committed today on the same terms as the Entitlement Offer, primarily from Mesoblast's existing major shareholders.
紐約，2024年3月13日（GLOBE NEWSWIRE）——炎症性疾病異基因細胞藥物的全球領導者Mesoblast Limited（納斯達克股票代碼：MSO；澳大利亞證券交易所股票代碼：MSB）今天宣佈，已收到堅定承諾，將完成於2023年12月4日推出的按比例加速不可放棄的福利優惠（權利優惠）。配股發行和機構配售共籌集了9,700萬澳元的總收益，其中包括今天承諾的3670萬澳元，其條款與權利要約相同，主要來自Mesoblast的現有主要股東。
Dr. Eric Rose, the Company's Chief Medical Officer and a director of Mesoblast, subscribed for additional shares of A$1.5 million, subject to shareholder approval. Dr. Rose is a world-renowned heart surgeon who performed the world's first successful heart transplant in children and was for many years Chairman of Columbia University's Department of Surgery. Dr. Rose was the Principal Investigator of the pivotal trial resulting in FDA approval of the first implantable left ventricular assist device (LVAD) for long term support of patients with heart failure, spawning an entire new industry.
該公司首席醫療官兼Mesoblast董事埃裏克·羅斯博士額外認購了150萬澳元的股份，但須經股東批准。羅斯博士是世界知名的心臟外科醫生，他成功進行了世界上第一次兒童心臟移植手術，並曾擔任哥倫比亞大學外科系主任多年。羅斯博士是這項關鍵試驗的首席研究員，該試驗使美國食品藥品管理局批准了第一款用於長期支持心力衰竭患者的植入式左心室輔助設備（LVAD），催生了一個全新的行業。